An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 4, 2008, Pages 695-702

  Gabizon, Alberto ^a,b   Isacson, Rut ^a   Rosengarten, Ora ^a   Tzemach, Dina ^a   Shmeeda, Hilary ^a   Sapir, Rama ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Doxorubicin; Liposome; Open label clinical study; Pegylation; Pharmacokinetics

Indexed keywords

DOXORUBICIN;

ADULT; AGED; ANALYSIS OF VARIANCE; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; ASCITES; BREAST CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PARAMETER; PRIORITY JOURNAL; PROSTATE CARCINOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; STATISTICAL ANALYSIS; STOMACH CARCINOMA; STOMATITIS; STUDENT T TEST; THYMOMA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MIDDLE AGED; NEOPLASMS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 38049019767     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0525-5     Document Type: Article

References (31)

1. Alberts DS, Muggia FM, Carmichael J et al (2004) Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31:53
2. Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1068:133
3. Amantea M, Newman MS, Sullivan TM et al (1999) Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs. Hum Exp Toxicol 18:17
4. Amantea MA, Forrest A, Northfelt DW et al (1997) Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther 61:301
5. Berry G, Billingham M, Alderman E et al (1998) The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 9:711
6. Briasoulis E, Karavasilis V, Tzamakou E et al (2004) Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol 53:452
7. Charrois GJ, Allen TM (2003) Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J Pharmacol Exp Ther 306:1058
8. Chin DL, Lum BL, Sikic BI (2002) Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 779:259
9. Colbern GT, Hiller AJ, Musterer RS et al (1999) Significant increase in antitumor potency of doxorubicin HCI by its encapsulation in pegylated liposomes. J Liposome Res 9:523
10. Coleman RE, Biganzoli L, Canney P et al (2006) A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 42:882
11. Da Ros L, Squassante L, Milleri S (2003) Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. Clin Pharmacokinet 42:99
12. Gabizon A, Catane R, Uziely B et al (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987
13. Gabizon A, Goren D, Horowitz AT et al (1997) Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 24:337
14. Gabizon A, Shmeeda H, Barenholz Y (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419
15. Gabizon A, Tzemach D, Mak L et al (2002) Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 10:539
16. Gabizon AA (1995) Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 16:285
17. Gabizon AA, Lyass O, Berry GJ et al (2004) Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest 22:663
18. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312
19. Hamilton A, Biganzoli L, Coleman R et al (2002) EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. Ann Oncol 13:910
20. Huang SK, Lee KD, Hong K et al (1992) Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 52:5135
21. 2) in the treatment of gynecologic cancers. Gynecol Oncol 97:374
22. Lotem M, Hubert A, Lyass O et al (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136:1475
23. Lyass O, Hubert A, Gabizon AA (2001) Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies. Clin Cancer Res 7:3040
24. Lyass O, Uziely B, Ben-Yosef R et al (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037
25. Marina NM, Cochrane D, Harney E et al (2002) Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res 8:413
26. O'Brien ME, Wigler N, Inbar M et al (2004) Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15:440
27. 2. Ann Oncol 11:1029
28. Storm G, ten Kate MT, Working PK et al (1998) Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin Cancer Res 4:111
29. Uziely B, Jeffers S, Isacson R et al (1995) Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777
30. Vail DM, Amantea MA, Colbern GT et al (2004) Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 31:16
31. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochim Biophys Acta 1113:171